Eli Lilly (NYSE:LLY) is taking the unusual step of asking people who took compounded versions of their drug tirzepatide, ...

Global Home Respiratory Therapy Market is valued at approximately USD 8.55 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 6.72% over the forecast period 2024-2032.

In a high-flying market, finding ASX value shares with a balance of quality fundamentals and growth is key, Let's dive in.

ResMed faces a 3% drop in share price after concerns over Eli Lilly’s Ozempic, which could impact the demand for CPAP ...

The Resmed CDI (ASX:RMD) share price has jumped 39.1% since the start of the 2024. The Netwealth Group Ltd (ASX:NWL) share ...

Shares of ResMed Inc. RMD rallied 2.08% to $242.98 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and the ...

Wolfe Research has recently reduced Resmed Inc (RMD) stock to Underperform rating, as announced on September 18, 2024, according to Finviz. Earlier, on September 4, 2024, Needham had reduced the stock ...